Compounds > bezafibrate
Page last updated: 2024-08-23

bezafibrate and clofibric acid

bezafibrate has been researched along with clofibric acid in 131 studies

Research

Studies (131)

TimeframeStudies, this research(%)All Research%
pre-199065 (49.62)18.7374
1990's32 (24.43)18.2507
2000's26 (19.85)29.6817
2010's8 (6.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abraham, DJ; Kennedy, PE; Mehanna, AS; Patwa, DC; Williams, FL1
Brown, PJ; Chapman, JM; Kliewer, SA; Koble, CS; Lehmann, JM; Lewis, MC; Moore, LB; Plunket, KD; Sundseth, SS; Willson, TM; Wilson, JG; Winegar, DA; Wu, Z1
Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX1
Maillet, EL; Margolskee, RF; Mosinger, B1
Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T1
Bolzano, K; Krempler, F; Schellenberg, B; Schlierf, G1
Amiconi, G; Ascenzi, P; Bertollini, A; Coletta, M; Desideri, A; Polizio, F; Santucci, R1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, RM1
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, R1
Cannon, JR; Eacho, PI1
Eacho, PI; Foxworthy, PS; Hoover, DM; White, SL1
Frishman, WH; Kahn, S; Zimetbaum, P1
Kłosiewicz-Latoszek, L; Szostak, WB1
Clerc, C; Cloarec, L; Doualin, G; Fertil, V; Legras, B; Ruelland, A1
Bonner, FW; Gibson, GG; Makowska, JM1
Angelin, B; Einarsson, K; Ståhlberg, D1
Bonner, FW; Eason, CT; Henry, G; Pattison, A; Powles, P; Spencer, AJ1
Agius, L; Alberti, KG; Gerondaes, P2
Krause, BR; Newton, RS1
Bonner, FW; Eason, CT; Howells, DD; Pattison, A; Spencer, AJ1
Palmer, RH1
Hunninghake, DB; Peters, JR1
Eacho, PI; Foxworthy, PS1
Boag, DE; Lorimer, AR; Packard, CJ; Shepherd, J; Stewart, JM1
Honková, M; Kunesová, M; Mares, P; Skorepa, J; Zeman, M1
Franceschini, G; Paoletti, R; Sirtori, CR1
Rüth, E; Vollmar, J1
Fischer, H; Oster, P; Roche, A; Schellenberg, B; Schlierf, G; Stiehl, A; Vollmar, J1
Canzler, H1
Keller, M; Lang, PD; Middelhoff, G; Mordasini, R; Oster, P; Riesen, W1
Holler, HD; Janka, HU; Mehnert, H; Standl, A1
Dorda, W; Kostner, GM; Mühlhauser, I; Prager, R; Schernthaner, G; Zechner, R1
Lang, PD; Vollmar, J1
Day, AJ; Hudson, K; Mojumder, S1
Kurlat, MI; Neuman, J; Neuman, MP1
Djaja, S; Machalke, K; Richter, E1
Fahimi, HD; Hartig, F; Ozel, M; Reinicke, A; Stegmeier, K; Sujatta, M; Yokota, S1
Lageder, H1
Abshagen, U; Marinow, J; Spörl-Radun, S1
Boberg, J; Gustafsson, IB; Hellsing, K; Ledermann, H; Lithell, H; Ostlund-Lindqvist, AM; Vessby, B1
Kokot, F; Szczechowska, E1
Dick, TB; Ledermann, HM; Marples, J; Whittington, J1
Grützmacher, P; Lang, W; Scheuermann, E1
Mordasini, R; Oster, P; Riesen, W; Riva, G1
Day, AJ; Hudson, K; Marceglia, A1
Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG1
Drosner, M; Janetschek, P; Schwandt, P; Weisweiler, P1
Lazarow, PB; Leroy-Houyet, MA; Shio, H1
Lang, PD; Mertz, DP; Vollmar, J1
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K1
Stratmann, FW1
Ledermann, H; Lithell, H; Vessby, B1
Heidland, A; Hörl, M; Hörl, WH1
Anderson, P; Norbeck, HE2
Fringes, B; Riede, UN; von Deimling, O1
Day, AJ; Hudson, K1
Braeuning, C; Middelhoff, G; Schlierf, G; Wirth, A1
Kłosiewicz-Latoszek, L; Naruszewicz, M; Nowicka, G; Szostak, WB1
Hofmann, H; Holler, HD; Stratmann, FW1
Bertuletti, R; Carini, M; Maffei, FR; Tofanetti, O1
Schwandt, P; Weisweiler, P1
Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG2
Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R1
Seidel, D; Walli, AK1
Bock, KD; Heidemann, H1
Kjellin, KG; Ledermann, H; Noring, L1
Bruneder, H; Klein, HJ1
Bock, KD1
Fährenkemper, T; Foerster, EC; Graf, P; Rabe, U; Sies, H1
Kaufmann, B; Ledermann, H1
Carini, M; Facino, RM1
Abshagen, U; Kaufmann, B; Kösters, W; Lang, PD1
Bachmann, C; Fragiacomo, C; Noseda, G; Weidmann, P1
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W1
Mertz, DP1
Schonfeld, G1
Dujovne, CA; Lozada, A1
Capps, NE1
Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C2
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Sánchez, RM; Vázquez, M; Viñals, M2
Shepherd, J1
Armitage, M; McLeod, AJ; Warren, RJ1
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W1
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM1
Galloway, SM; Johnson, TE; Ledwith, BJ; Manam, S; Nichols, WW; Pauley, CJ; Wagner, LK1
Nishimaki-Mogami, T; Okochi, E; Suzuki, K; Takahashi, A1
Nishimaki-Mogami, T; Suzuki, K; Takahashi, A1
Betteridge, DJ; O'Bryan-Tear, CG1
Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP1
de Wit, EC; Huisman, H; Kaptein, A; Neele, DM; Princen, HM1
Sinzinger, H1
Wallace, KB; Zhou, S1
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T1
Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Papadakis, JA; Winder, AF1
Bottoni, P; Ficarra, S; Giardina, B; Nocca, G; Puggioni, P; Remiddi, F; Rumi, C; Scatena, R; Sole, PD1
Madden, BP; Millner, R; Parker, J; Rolfe, LM; Seymour, CA; Sharobeem, KM1
Cabrero, A; Ciudad, CJ; Laguna, JC; Noé, V; Rodríguez, C1
Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C1
Adzet, T; Cabrero, A; Ciudad, CJ; Laguna, JC; Rodríguez, C; Roglans, N; Sánchez, RM; Vázquez, M1
Doolman, R; Gavendo, S; Harats, D; Marko, D; Sela, BA; Shaish, A; Yodfat, O1
Bargman, JM; Lipscombe, J1
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V1
Gervois, PP; Kleemann, R; Kooistra, T; Princen, HM; Staels, B; Verschuren, L1
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A1
Bottoni, P; De Sole, P; Ferrari, F; Giardina, B; Martorana, GE; Rossi, C; Scatena, R1
Aguilar, C; Borrull, F; Calull, M; Macià, A1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A1
Elisaf, MS; Mikhailidis, DP; Milionis, HJ1
Hauzer, A; Komsta, Ł; Majchrzak, E; Misztal, G1
Duriez, P; Fruchart, JC1
Boverhof, R; Jonkers, IJ; Kuipers, F; Masclee, AA; Princen, HM; Romijn, JA; Smelt, AH; Stellaard, F1
Battler, A; Behar, S; Benderly, M; Boyko, V; Goldbourt, U; Goldenberg, I; Haim, M; Tanne, D1
Berneis, K; Rizzo, M1
Nagao, M; Oikawa, S1
Caminada, D; Fent, K; Galicia, H; Weston, A1
Abadie, C; Alvergnas, M; Blanchard, N; Gallemann, D; Heyd, B; Mantion, G; Martin, H; Richert, L1
Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL1
Davidson, MH1
Kawashima, Y; Kudo, N; Mitsumoto, A; Okada, H; Sakamoto, T; Sunaga, K; Tsuda, T; Yamazaki, T1
Ikeda, E; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Tanaka, S; Wakabayashi, M; Yamazaki, T1
Kunkel, U; Radke, M; Riml, J; Wörman, A1
Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T1
Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T1
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S1
Fang, J; Guo, K; Hou, S; Hua, Z; Kong, X; Li, X; Ren, Z; Wu, Z1

Reviews

13 review(s) available for bezafibrate and clofibric acid

ArticleYear
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Journal of clinical pharmacology, 1991, Volume: 31, Issue:1

    Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides

1991
Effects of fibric acid derivatives on biliary lipid composition.
    The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B

    Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation

1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B

    Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids

1987
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Atherosclerosis, 1994, Volume: 111, Issue:2

    Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors

1994
Drug interactions with fibric acids.
    Pharmacology & therapeutics, 1994, Volume: 63, Issue:2

    Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids

1994
Mechanism of action of fibrates.
    Postgraduate medical journal, 1993, Volume: 69 Suppl 1

    Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL

1993
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
    Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38

    Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis

1998
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
    Current medical research and opinion, 2000, Volume: 16, Issue:1

    Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Ischemia; Randomized Controlled Trials as Topic; Triglycerides

2000
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides

2006
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
    Current medical research and opinion, 2007, Volume: 23, Issue:5

    Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome

2007
[Intervention for hypertriglyceridemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jul-28, Volume: 65 Suppl 7

    Topics: Aged; Bezafibrate; Clofibric Acid; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Niacin

2007
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
    The American journal of medicine, 2009, Volume: 122, Issue:10

    Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome

2009
Fibrates for primary prevention of cardiovascular disease events.
    The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11

    Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke

2016

Trials

21 trial(s) available for bezafibrate and clofibric acid

ArticleYear
Effects of fibric acid derivatives on biliary lipid composition.
    The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B

    Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation

1987
[Therapeutic effects of bezafibrate in hyperlipidemia].
    Casopis lekaru ceskych, 1983, May-20, Volume: 122, Issue:20

    Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged

1983
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
    The American journal of cardiology, 1983, Aug-22, Volume: 52, Issue:4

    Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship

1983
[The effect of bezafibrate on biliary lipids (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1980, Feb-01, Volume: 122, Issue:5

    Topics: Adult; Bezafibrate; Bile; Clofibrate; Clofibric Acid; Drug Evaluation; Humans; Hyperlipoproteinemias; Lipids

1980
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
    MMW, Munchener medizinische Wochenschrift, 1982, May-28, Volume: 124, Issue:21

    Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Glyburide; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Patient Compliance

1982
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Atherosclerosis, 1982, Volume: 43, Issue:2-3

    Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Diabetes Mellitus; Female; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Phosphatidylcholine-Sterol O-Acyltransferase

1982
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Therapie der Gegenwart, 1982, Volume: 121, Issue:5

    Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Theophylline; Xanthinol Niacinate

1982
[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Wiener klinische Wochenschrift, 1980, Feb-01, Volume: 92, Issue:3

    Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; Placebos; Triglycerides

1980
Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    European journal of clinical pharmacology, 1980, Volume: 17, Issue:4

    Topics: Administration, Oral; Adult; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Half-Life; Humans; Hypolipidemic Agents; Kinetics

1980
[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1981, Jul-01, Volume: 36, Issue:13

    Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation; Triglycerides

1981
Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Current medical research and opinion, 1981, Volume: 7, Issue:8

    Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Urea

1981
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, 1981, Volume: 18

    Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Triglycerides

1981
[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
    Schweizerische medizinische Wochenschrift, 1982, Jan-16, Volume: 112, Issue:3

    Topics: Adult; Apoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibric Acid; Colestipol; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Male; Middle Aged; Probucol

1982
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17

    Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates

1982
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Atherosclerosis, 1982, Volume: 45, Issue:3

    Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Female; Galactans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Mannans; Middle Aged; Plant Gums; Polysaccharides

1982
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Dec-04, Volume: 106, Issue:49

    Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Phospholipids; Placebos; Triglycerides

1981
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Clinical cardiology, 1995, Volume: 18, Issue:11

    Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides

1995
Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Postgraduate medical journal, 1996, Volume: 72, Issue:854

    Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-Action Preparations; Female; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Triglycerides

1996
Homocysteine elevation with fibrates: is it a class effect?
    The Israel Medical Association journal : IMAJ, 2001, Volume: 3, Issue:4

    Topics: Adult; Bezafibrate; Clofibric Acid; Dietary Fats; Female; Fibric Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides

2001
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
    The Journal of nutrition, 2006, Volume: 136, Issue:4

    Topics: Bezafibrate; Bile Acids and Salts; Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Cholesterol; Cholic Acid; Clofibric Acid; Cross-Over Studies; Fasting; Fish Oils; Gallstones; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Triglycerides

2006
Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
    Coronary artery disease, 2006, Volume: 17, Issue:5

    Topics: Aged; Bezafibrate; Clofibric Acid; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Secondary Prevention; Triglycerides

2006

Other Studies

98 other study(ies) available for bezafibrate and clofibric acid

ArticleYear
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
    Journal of medicinal chemistry, 1984, Volume: 27, Issue:8

    Topics: Acetates; Animals; Antisickling Agents; Benzyl Compounds; Binding Sites; Glycolates; Humans; Mice; Models, Molecular; Oxygen; Phenoxyacetates; Structure-Activity Relationship; X-Ray Diffraction

1984
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
    Journal of medicinal chemistry, 1999, Sep-23, Volume: 42, Issue:19

    Topics: Animals; Butyrates; DNA-Binding Proteins; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Nuclear Proteins; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Zinc Fingers

1999
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
    Journal of medicinal chemistry, 2007, Feb-22, Volume: 50, Issue:4

    Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides

2007
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
    Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21

    Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Benzene Derivatives; Bezafibrate; Cell Line; Cercopithecidae; Clofibric Acid; Gemfibrozil; Herbicides; Humans; Hypolipidemic Agents; Indoleacetic Acids; Mice; Protein Subunits; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Structure-Activity Relationship

2009
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney

2011
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Acta medica Austriaca, 1979, Volume: 6, Issue:3

    Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged

1979
Effect of bezafibrate and clofibric acid on the spectroscopic properties of the nitric oxide derivative of ferrous human hemoglobin.
    Journal of inorganic biochemistry, 1992, Oct-01, Volume: 48, Issue:1

    Topics: 2,3-Diphosphoglycerate; Bezafibrate; Clofibric Acid; Diphosphoglyceric Acids; Electron Spin Resonance Spectroscopy; Ferrous Compounds; Hemoglobins; Humans; Molecular Structure; Nitric Oxide; Phytic Acid; Protein Conformation; Spectrophotometry; Spectrum Analysis

1992
Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro.
    Biochemical pharmacology, 1992, Feb-04, Volume: 43, Issue:3

    Topics: Animals; Bezafibrate; Clofibric Acid; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Palmitoyl Coenzyme A; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Subcellular Fractions

1992
In vitro effect of clofibric acid derivatives on rat hepatic microsomal electron transport chains.
    Biochemical pharmacology, 1991, Oct-24, Volume: 42, Issue:10

    Topics: Animals; Bezafibrate; Clofibric Acid; Cytochromes b5; Electron Transport; Gemfibrozil; Kinetics; Male; Microsomes, Liver; NADH Dehydrogenase; NADPH Dehydrogenase; Rats; Rats, Inbred Strains

1991
Interaction of LY171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver.
    The Biochemical journal, 1991, Dec-01, Volume: 280 ( Pt 2)

    Topics: Acetophenones; Animals; Bezafibrate; Carrier Proteins; Clofibric Acid; Electrophoresis, Polyacrylamide Gel; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fibric Acids; Male; Microbodies; Neoplasm Proteins; Nerve Tissue Proteins; Oleic Acid; Oleic Acids; Pyrimidines; Rats; Rats, Inbred F344; SRS-A; Tetrazoles

1991
Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
    Toxicology and applied pharmacology, 1990, Volume: 104, Issue:3

    Topics: Acetophenones; Animals; Autacoids; Azoles; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Dexamethasone; Dogs; Dose-Response Relationship, Drug; Female; Fibric Acids; Glucagon; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Microbodies; Microscopy, Electron; NAD; Oxidation-Reduction; Rats; Tetrazoles; Tyrosine Transaminase

1990
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:1

    Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol

1991
Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
    Clinical chemistry, 1990, Volume: 36, Issue:3

    Topics: Apolipoprotein A-I; Apolipoproteins A; Bezafibrate; Clofibric Acid; Drug Therapy, Combination; Fibric Acids; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Probucol

1990
Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens.
    Xenobiotica; the fate of foreign compounds in biological systems, 1990, Volume: 20, Issue:11

    Topics: Animals; Bezafibrate; Clofibric Acid; Fibric Acids; Glutathione Peroxidase; Hepatomegaly; Hypolipidemic Agents; Liver; Male; Microbodies; Rats

1990
Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes.
    Journal of lipid research, 1989, Volume: 30, Issue:7

    Topics: Animals; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Clofibric Acid; Fibric Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Male; Microsomes, Liver; Rats; Rats, Inbred Strains; Sterol O-Acyltransferase

1989
The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat.
    Xenobiotica; the fate of foreign compounds in biological systems, 1989, Volume: 19, Issue:8

    Topics: Administration, Oral; Animals; Bezafibrate; Clofibric Acid; Dose-Response Relationship, Drug; Fibric Acids; Gastric Mucosa; Gastrins; Hypolipidemic Agents; Male; Neurosecretory Systems; Rats; Rats, Inbred F344; Stomach Ulcer

1989
Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
    The Biochemical journal, 1988, Jul-01, Volume: 253, Issue:1

    Topics: Animals; Bezafibrate; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Cells, Cultured; Clofibrate; Clofibric Acid; Fatty Acids; Fibric Acids; Glucagon; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Rats; Rats, Inbred Strains

1988
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
    Atherosclerosis, 1986, Volume: 59, Issue:1

    Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates

1986
Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
    Scandinavian journal of gastroenterology, 1988, Volume: 23, Issue:9

    Topics: Administration, Oral; Animals; Bezafibrate; Carcinoid Tumor; Clofibrate; Clofibric Acid; Fibric Acids; Gastric Juice; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred F344; Species Specificity; Stomach Neoplasms; Time Factors

1988
Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes.
    The Biochemical journal, 1988, Jul-01, Volume: 253, Issue:1

    Topics: Acyltransferases; Animals; Bezafibrate; Carnitine O-Palmitoyltransferase; Cells, Cultured; Clofibrate; Clofibric Acid; Epoxy Compounds; Ethers, Cyclic; Fatty Acids; Fibric Acids; Isoenzymes; Liver; Male; Rats; Rats, Inbred Strains; Time Factors; Triglycerides

1988
Conditions influencing the induction of peroxisomal beta-oxidation in cultured rat hepatocytes.
    Toxicology letters, 1986, Volume: 30, Issue:2

    Topics: Animals; Bezafibrate; Catalase; Cell Survival; Clofibric Acid; Fibric Acids; Gemfibrozil; In Vitro Techniques; Liver; Male; Microbodies; Pentanoic Acids; Rats; Rats, Inbred F344

1986
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
    Atherosclerosis, 1982, Volume: 44, Issue:3

    Topics: Adult; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Receptors, Cell Surface; Receptors, LDL

1982
[Improvement in diabetes control by treatment with bezafibrate].
    Deutsche medizinische Wochenschrift (1946), 1982, Oct-01, Volume: 107, Issue:39

    Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Insulin; Male; Sulfonylurea Compounds; Triglycerides

1982
[Drug therapy of hypercholesterinemias (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1980, Mar-28, Volume: 122, Issue:13

    Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; Humans; Hypercholesterolemia; Neomycin; Nicotinic Acids; Sitosterols

1980
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Atherosclerosis, 1981, Volume: 40, Issue:2

    Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides

1981
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Deutsche medizinische Wochenschrift (1946), 1983, Feb-25, Volume: 108, Issue:8

    Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides

1983
The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins.
    Experimental and molecular pathology, 1983, Volume: 38, Issue:1

    Topics: Animals; Ascitic Fluid; Bezafibrate; Cholesterol Esters; Clofibrate; Clofibric Acid; Lipoproteins, LDL; Macrophages; Rabbits; Sterol Esterase; Sterol O-Acyltransferase

1983
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Current medical research and opinion, 1983, Volume: 8, Issue:5

    Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Triglycerides

1983
The short- and long-term effects of bezafibrate in the rat.
    Annals of the New York Academy of Sciences, 1982, Volume: 386

    Topics: Animals; Bezafibrate; Carnitine O-Acetyltransferase; Catalase; Cholesterol; Clofibrate; Clofibric Acid; Female; Hypolipidemic Agents; Kinetics; Liver; Male; Microbodies; Microscopy, Electron; Organ Size; Organoids; Rats; Rats, Inbred Strains; Triglycerides

1982
Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
    Atherosclerosis, 1980, Volume: 37, Issue:2

    Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Esters; Fatty Acids; Female; Humans; Insulin; Lipids; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides

1980
The effect of bezafibrate and clofibrate on cholesterol ester metabolism in 3T3 cells in smooth muscle cells in tissue culture.
    Experimental and molecular pathology, 1982, Volume: 36, Issue:2

    Topics: Animals; Aorta; Bezafibrate; Cell Line; Cholesterol; Cholesterol Esters; Clofibrate; Clofibric Acid; Culture Techniques; Lipoproteins, LDL; Mice; Muscle, Smooth, Vascular; Swine

1982
[Bezafibrate in primary hyperlipidemias (author's transl)].
    Klinische Wochenschrift, 1982, Jan-15, Volume: 60, Issue:2

    Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hyperlipoproteinemias; Lipoprotein Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged

1982
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Atherosclerosis, 1982, Volume: 42, Issue:2-3

    Topics: Apolipoprotein C-I; Apolipoprotein C-II; Apolipoproteins; Apolipoproteins C; Apolipoproteins E; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Protein Conformation; Triglycerides

1982
Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat.
    Journal of lipid research, 1982, Volume: 23, Issue:2

    Topics: Animals; Bezafibrate; Cell Division; Cell Fractionation; Clofibrate; Clofibric Acid; Female; Hepatomegaly; Hypolipidemic Agents; Male; Microbodies; Organ Size; Organoids; Rats; Rats, Inbred F344; Sex Factors

1982
Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
    Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 1982, Volume: 180, Issue:1

    Topics: Bezafibrate; Clofibrate; Clofibric Acid; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Isoenzymes; Kidney; Male; Middle Aged; Muscle Proteins; Muscles; Myoglobinuria

1982
[What are the possibilities in the treatment of primary hyperlipidemia in diabetes mellitus?].
    Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17

    Topics: Bezafibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents

1982
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Atherosclerosis, 1982, Volume: 44, Issue:1

    Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Muscles

1982
[Fat and renal failure--therapeutic aspects].
    Klinische Wochenschrift, 1982, Volume: 60, Issue:15

    Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Infusions, Parenteral; Kidney Failure, Chronic; Lipids; Physical Exertion; Rats; Renal Dialysis

1982
Treatment of uremic hypertriglyceridaemia with bezafibrate.
    Atherosclerosis, 1982, Volume: 44, Issue:2

    Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipid Metabolism; Lipoproteins; Male; Triglycerides

1982
Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
    Atherosclerosis, 1982, Volume: 44, Issue:3

    Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Microbodies; Rats; Time Factors

1982
The effect of bezafibrate and clofibrate on microsomal ACAT and lysosomal cholesterol ester hydrolase activity in the cholesterol-fed rabbit aorta.
    Atherosclerosis, 1982, Volume: 45, Issue:1

    Topics: Acyltransferases; Animals; Aorta; Bezafibrate; Carboxylic Ester Hydrolases; Clofibrate; Clofibric Acid; Female; Hypolipidemic Agents; Lysosomes; Rabbits; Regression Analysis; Sterol Esterase; Sterol O-Acyltransferase

1982
[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Kardiologia polska, 1982, Volume: 25, Issue:7-8

    Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged; Triglycerides

1982
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
    Die Medizinische Welt, 1981, Feb-20, Volume: 32, Issue:8

    Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Placebos

1981
"In vitro" metabolism of bezafibrate by rat liver.
    Pharmacological research communications, 1981, Volume: 13, Issue:2

    Topics: Animals; Bezafibrate; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Hydroxylation; Hypolipidemic Agents; In Vitro Techniques; Kinetics; Liver; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Rats; Subcellular Fractions

1981
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Artery, 1980, Volume: 7, Issue:6

    Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type IV; Lipids; Lipoproteins, HDL; Male; Middle Aged; Triglycerides

1980
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Artery, 1980, Volume: 8, Issue:6

    Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Inositol; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nicotinic Acids; Nicotinyl Alcohol; Xanthinol Niacinate

1980
Clinical experience with bezafibrate.
    Artery, 1980, Volume: 8, Issue:6

    Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Triglycerides

1980
Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 1981, Volume: 179, Issue:2

    Topics: Alkaline Phosphatase; Animals; Bezafibrate; Bilirubin; Clofibrate; Clofibric Acid; Glucuronates; Glucuronosyltransferase; Hexosyltransferases; Hypolipidemic Agents; Liver; Male; Microsomes, Liver; Rats; Rats, Inbred Strains

1981
[Rhabdomyolysis with acute renal failure due to bezafibrate].
    Klinische Wochenschrift, 1981, Apr-15, Volume: 59, Issue:8

    Topics: Acute Kidney Injury; Bezafibrate; Clofibrate; Clofibric Acid; Humans; Male; Middle Aged; Muscular Diseases

1981
Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
    The Journal of international medical research, 1981, Volume: 9, Issue:5

    Topics: Adult; Bezafibrate; Cerebral Infarction; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Lipoproteins, HDL; Male; Middle Aged

1981
Acute muscular syndrome after bezafibrate.
    Klinische Wochenschrift, 1981, Dec-01, Volume: 59, Issue:23

    Topics: Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Humans; Hypolipidemic Agents; Myoglobinuria

1981
Peroxisomal fatty acid oxidation as detected by H2O2 production in intact perfused rat liver.
    The Biochemical journal, 1981, Jun-15, Volume: 196, Issue:3

    Topics: Animals; Bezafibrate; Catalase; Clofibric Acid; Fatty Acids; Hydrogen Peroxide; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Methanol; Microbodies; Organoids; Oxidation-Reduction; Perfusion; Rats; Rats, Inbred Strains

1981
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    European journal of clinical pharmacology, 1981, Volume: 21, Issue:3

    Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Kinetics; Male; Middle Aged

1981
Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    The Journal of international medical research, 1981, Volume: 9, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Humans; Hypolipidemic Agents; Kinetics; Male

1981
Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
    Pharmacological research communications, 1981, Volume: 13, Issue:9

    Topics: Animals; Bezafibrate; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Hypolipidemic Agents; Liver; Male; Mixed Function Oxygenases; Oxidoreductases; Rats; Rats, Inbred Strains; Spectrum Analysis

1981
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Klinische Wochenschrift, 1980, Sep-01, Volume: 58, Issue:17

    Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Kidney Diseases; Kinetics; Male; Middle Aged

1980
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Schweizerische medizinische Wochenschrift, 1980, Dec-06, Volume: 110, Issue:49

    Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Lipoproteins, HDL; Triglycerides

1980
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Artery, 1980, Volume: 8, Issue:2

    Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Inositol; Lipoproteins; Nicotinic Acids; Xanthinol Niacinate

1980
The effect of etofibrate retard, bezafibrate and procetofen.
    Artery, 1980, Volume: 8, Issue:2

    Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides

1980
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
    Fortschritte der Medizin, 1980, Dec-04, Volume: 98, Issue:45

    Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged

1980
Lipid profiles on fibric-acid derivatives.
    Lancet (London, England), 1994, Sep-03, Volume: 344, Issue:8923

    Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids

1994
Hypercholesterolemia treatment in a renal transplant patient.
    Clinical nephrology, 1994, Volume: 41, Issue:5

    Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin

1994
Creatinine rise after fibrate therapy in renal graft recipients.
    Lancet (London, England), 1993, Mar-27, Volume: 341, Issue:8848

    Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney Transplantation; Male

1993
Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro.
    Biochemical pharmacology, 1993, Nov-17, Volume: 46, Issue:10

    Topics: Acetyltransferases; Animals; Bezafibrate; Clofibric Acid; Cytosol; Fatty Acid Desaturases; Fatty Acid Elongases; Gemfibrozil; Liver; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley

1993
Cytosolic lipogenic enzymes: effect of fibric acid derivatives in vitro.
    Life sciences, 1993, Volume: 52, Issue:2

    Topics: Animals; Bezafibrate; Clofibric Acid; Cytosol; Enzyme Inhibitors; Fatty Acids; Gemfibrozil; Kinetics; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley

1993
Abnormal lipid profiles on fibrate derivatives.
    Lancet (London, England), 1996, Jan-27, Volume: 347, Issue:8996

    Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids

1996
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
    The Biochemical journal, 1996, Mar-15, Volume: 314 ( Pt 3)

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S

1996
Growth regulation by peroxisome proliferators: opposing activities in early and late G1.
    Cancer research, 1996, Jul-15, Volume: 56, Issue:14

    Topics: Animals; Bezafibrate; Carcinogens; Cell Cycle; Cell Line; Clofibrate; Clofibric Acid; DNA; Fibric Acids; Gene Expression Regulation; Genes, Immediate-Early; Growth Substances; Mice; Microbodies; Pyrimidines; Signal Transduction; Time Factors; Transcriptional Activation

1996
Bezafibrate and clofibric acid are novel inhibitors of phosphatidylcholine synthesis via the methylation of phosphatidylethanolamine.
    Biochimica et biophysica acta, 1996, Nov-11, Volume: 1304, Issue:1

    Topics: Animals; Bezafibrate; Butyrates; Cells, Cultured; Choline-Phosphate Cytidylyltransferase; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Liver; Methylation; Methyltransferases; Microsomes; Nucleotidyltransferases; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Phosphatidylethanolamines; Rats; Rats, Wistar; Sulfhydryl Reagents

1996
The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing
    Biochimica et biophysica acta, 1996, Nov-11, Volume: 1304, Issue:1

    Topics: Animals; Apolipoprotein B-48; Apolipoproteins B; Bezafibrate; Cells, Cultured; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanolamine; Ethanolamines; Female; Leucine; Lipoproteins, VLDL; Liver; Methylation; Methyltransferases; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Phosphatidylethanolamines; Rats; Rats, Wistar; Specific Gravity; Tubercidin

1996
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical applications, 1996, Dec-13, Volume: 687, Issue:2

    Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity

1996
No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased.
    Biochemical and biophysical research communications, 1998, Mar-17, Volume: 244, Issue:2

    Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Gemfibrozil; Humans; Liver; Macaca fascicularis

1998
The effect of peroxisome proliferators on mitochondrial bioenergetics.
    Toxicological sciences : an official journal of the Society of Toxicology, 1999, Volume: 48, Issue:1

    Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene

1999
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
    Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:6

    Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic

1999
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    International journal of cardiology, 1999, Jun-01, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibric Acids; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged; Pilot Projects; Treatment Outcome

1999
Bezafibrate as differentiating factor of human myeloid leukemia cells.
    Cell death and differentiation, 1999, Volume: 6, Issue:8

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Bezafibrate; Biomarkers; Cell Cycle; Cell Differentiation; Clofibric Acid; Gemfibrozil; Growth Inhibitors; HL-60 Cells; Humans; Integrin alphaXbeta2; K562 Cells; Leukemia, Myeloid; Lipopolysaccharide Receptors; U937 Cells

1999
Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group.
    Journal of cardiovascular pharmacology and therapeutics, 2000, Volume: 5, Issue:1

    Topics: Acute Kidney Injury; Aged; Anticholesteremic Agents; Bezafibrate; Cardiopulmonary Bypass; Clofibric Acid; Female; Fibric Acids; Humans; Male; Middle Aged; Rhabdomyolysis

2000
Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration.
    Molecular pharmacology, 2000, Volume: 58, Issue:1

    Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Biopolymers; Cell Nucleus; Cells, Cultured; Clofibric Acid; Cytosol; Fibric Acids; Guinea Pigs; Humans; Hypolipidemic Agents; Liver; Male; Nuclear Proteins; Oxidoreductases; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; Sp1 Transcription Factor; Transcription Factors

2000
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:12

    Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea

2000
Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.
    Biochemical pharmacology, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Bezafibrate; Clofibric Acid; Culture Media; Enzyme Induction; Fibric Acids; Humans; Hypolipidemic Agents; Liver; Male; Oxidoreductases; Rats; Rats, Sprague-Dawley; RNA, Messenger; Stearoyl-CoA Desaturase; Tumor Cells, Cultured

2001
Fibrate-induced increase in blood urea and creatinine.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7

    Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases

2001
Effects of various fibrates on serum alkaline phosphatase activity.
    Atherosclerosis, 2002, Volume: 165, Issue:1

    Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome

2002
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.
    Blood, 2003, Jan-15, Volume: 101, Issue:2

    Topics: Animals; Bezafibrate; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-beta; Cell Nucleus; Clofibric Acid; Down-Regulation; Fibric Acids; Hepatocytes; Humans; Hypolipidemic Agents; Interleukin-1; Mice; Mice, Knockout; NF-kappa B; NF-kappa B p50 Subunit; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcription, Genetic; Transfection

2003
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Naunyn-Schmiedeberg's archives of pharmacology, 2003, Volume: 367, Issue:3

    Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured

2003
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
    Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3

    Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents

2004
Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications.
    Biochemical and biophysical research communications, 2004, Jul-02, Volume: 319, Issue:3

    Topics: Bezafibrate; Cell Differentiation; Cell Division; Clofibric Acid; Dose-Response Relationship, Drug; Electron Transport; Gemfibrozil; HL-60 Cells; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Mitochondria; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors

2004
Determination of some acidic drugs in surface and sewage treatment plant waters by capillary electrophoresis-electrospray ionization-mass spectrometry.
    Electrophoresis, 2004, Volume: 25, Issue:20

    Topics: Acids; Bezafibrate; Clofibric Acid; Electrophoresis, Capillary; Naproxen; Pharmaceutical Preparations; Sewage; Spectrometry, Mass, Electrospray Ionization; Water Pollutants, Chemical

2004
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    American journal of hypertension, 2005, Volume: 18, Issue:11

    Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography

2005
Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.
    Journal of pharmaceutical and biomedical analysis, 2006, May-03, Volume: 41, Issue:2

    Topics: Bezafibrate; Buffers; Clofibric Acid; Electrophoresis, Capillary; Fibric Acids; Gemfibrozil; Hydrogen-Ion Concentration; Hypolipidemic Agents; Pharmaceutical Preparations; Reproducibility of Results; Temperature; Time Factors

2006
Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas).
    Environmental toxicology and chemistry, 2009, Volume: 28, Issue:12

    Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Clofibric Acid; Cyprinidae; Female; Hypolipidemic Agents; Lipid Metabolism; Male; Ovum; PPAR alpha; Vitellogenins; Water Pollutants, Chemical

2009
Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine.
    Toxicology in vitro : an international journal published in association with BIBRA, 2009, Volume: 23, Issue:7

    Topics: Acetylcysteine; Adult; Aged; Animals; Bezafibrate; Cells, Cultured; Clofibric Acid; Cytochrome P-450 CYP4A; Female; Gene Expression Regulation; Hepatocytes; Humans; Hypolipidemic Agents; Male; Middle Aged; Rats; Rats, Wistar; RNA, Messenger; Species Specificity

2009
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
    Cardiovascular drugs and therapy, 2009, Volume: 23, Issue:5

    Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome

2009
Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:1

    Topics: Animals; Bezafibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Fenofibrate; Gene Expression Regulation; Liver; Male; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase

2012
Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:9

    Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Bezafibrate; Clofibric Acid; Fatty Acids; Fenofibrate; Fibric Acids; Gene Expression; Gene Expression Regulation; Liver; Male; Microsomes, Liver; Phosphatidylcholines; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase

2012
Evaluating the fate of six common pharmaceuticals using a reactive transport model: insights from a stream tracer test.
    The Science of the total environment, 2013, Aug-01, Volume: 458-460

    Topics: Adsorption; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Ibuprofen; Metoprolol; Models, Theoretical; Naproxen; Pharmaceutical Preparations; Rivers; Sensitivity and Specificity; Sweden; Tandem Mass Spectrometry; Water Movements; Water Pollutants, Chemical

2013
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.
    Journal of pharmacological sciences, 2013, Volume: 123, Issue:4

    Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; Male; Molecular Targeted Therapy; PPAR alpha; Rats; Rats, Wistar; Triglycerides; Up-Regulation

2013
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:1

    Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger

2014
Degradation of lipid regulators by the UV/chlorine process: Radical mechanisms, chlorine oxide radical (ClO
    Water research, 2018, 06-15, Volume: 137

    Topics: Ammonia; Bezafibrate; Chlorine; Chlorine Compounds; Clofibric Acid; Disinfection; Gemfibrozil; Halogenation; Hydroxyl Radical; Hypolipidemic Agents; Kinetics; Oxidation-Reduction; Photolysis; Ultraviolet Rays; Vibrio; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification

2018